Deuruxolitinib: a new entry in the dm+d dictionary
The NHS Business Services Authority has added deuruxolitinib to the dm+d (dictionary of medicines and devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of targeted immunosuppressant drugs.
What is it used for?
Deuruxolitinib is indicated for the treatment of atopic dermatitis. It works by selectively inhibiting JAK1, a key enzyme involved in inflammatory pathways that drive atopic skin disease.
Event medicine relevance
Deuruxolitinib is not currently licensed for use in the UK and is not available on the NHS. Medical Responders should not administer this agent at events.
However, event medics may encounter patients who report taking this medication if they have obtained it privately or from overseas sources. If a patient discloses use of deuruxolitinib:
- Take a brief medication history and note the dose and frequency
- Assess for any acute dermatological exacerbation or systemic symptoms
- Advise the patient to seek specialist dermatology review at their earliest opportunity
- If acute exacerbation of atopic dermatitis occurs or the patient reports systemic symptoms, arrange conveyance to hospital for specialist assessment
Key cautions
As a JAK inhibitor, deuruxolitinib carries the class-wide risks associated with immunosuppression. Patients taking JAK inhibitors may have increased susceptibility to infection and require careful monitoring. Always verify current licensing status and clinical guidance before considering any clinical decision.
Further information
For the latest prescribing information and UK licensing status, consult the BNF and the MHRA website.
View the full NHS dm+d dictionary at NHS BSA dm+d.